Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Enterin Inc.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04483479CT.gov Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover) | — | Terminated | — | — | — |
NCT03781791CT.gov Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET) | — | Completed | — | — | — |
NCT03047629CT.gov Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Constipation Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ent-01 (this asset) | Enterin Inc. | P2 | B · 62 |
| N-Methylnaltrexone Bromide | Bausch Health Americas, Inc. | P3 | BB |
| Moa-728 | Bausch Health Americas, Inc. | P2 | BB |
| Lubiprostone | University of Rochester | P4 | BB |
| Oxycodone | Mundipharma Research GmbH & Co KG | P3 | BB |
| 17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE | Mundipharma Research GmbH & Co KG | P3 | BB |
| Oxycodone Hydrochloride, Hydrocodone- | University of Illinois College of Medicine at Peoria | P4 | BB |
| Polyethylene Glycol 3350 | Chad R. Tracy | P4 | BB |
| Marcaine | University of Illinois College of Medicine at Peoria | P4 | BB |
+20 more in the Constipation Disorder cohort
Other indications for Ent-01
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Parkinson Disease | — | P2 | B · 56 |
| Dementia | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ent-01 in Constipation Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ent-01-constipation-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →